Group 1 - SMIC reported a net profit of 1.22 billion yuan for Q4 2025, representing a year-on-year increase of 23.2% [22][23] - The company achieved an operating revenue of 17.81 billion yuan, up 11.9% year-on-year [23] - The growth in performance is attributed to increased wafer sales volume, higher capacity utilization, and changes in product mix [23] Group 2 - Ge Wei Dong subscribed to a private placement of Jianghuai Automobile, investing approximately 1 billion yuan for 20.05 million shares at a price of 49.88 yuan per share [2] - Jianghuai Automobile raised a total of about 3.5 billion yuan through this issuance [2] Group 3 - Jia Mei Packaging announced that it may apply for a trading suspension again if its stock price experiences further abnormal increases, following a 567.11% price increase from December 17, 2025, to February 10, 2026 [3] - The company has been under close monitoring by the Shenzhen Stock Exchange due to significant price fluctuations [3] Group 4 - Lifan Pharmaceutical participated in a national centralized procurement process and expects to be selected for three products, which generated a total sales revenue of 14 million yuan in the first three quarters of 2025, accounting for 12.98% of its total revenue [5] Group 5 - ST Xuefa's related party, Xuesong Holdings, and its actual controller Zhang Jin were involved in a public fundraising fraud case, but the company stated that the case would not significantly impact its daily operations [6] Group 6 - Chu Tian Long plans to raise up to 760 million yuan through a private placement to fund projects related to innovative application security products and digital operations [7] Group 7 - Dong A Ejiao intends to invest 1.485 billion yuan in a health consumer goods industrial park project, focusing on the production of health food and related logistics [12] Group 8 - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium subsidiary due to reduced demand, but it is expected to have no significant impact on the company's operations [16] Group 9 - China Railway Construction recently won 10 major projects with a total value of 45.142 billion yuan, which represents 4.23% of its audited revenue for 2024 [21] Group 10 - New City Holdings reported a contract sales amount of approximately 714 million yuan in January 2026, a decrease of 29.79% year-on-year [27]

智通财经APP讯，东阿阿胶(000423.SZ)发布公告，公司拟以14.85亿元(其中固定资产投资14.21亿元，铺 底流动资金0.64亿元)的自有资金投资建设健康消费品产业园项目，用于药食同源食品、保健品、功能 性食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣及药品成品仓储等。 公司董事会决议授权管理层具体推进落实该项目，包括但不限于进一步完善规划设计、细化投资测算、 建设施工，以及办理其他与本投资事项相关的一切事宜。 ...

东阿阿胶表示，项目建设符合东阿阿胶健康消费品业务发展的迫切需要。健康消费品业务具有需求多样 化、产品迭代快等特点，对研发、质量、敏捷供应链等具有更高要求，公司现有产业园存在扩产面积受 限、主要产线面临产能瓶颈等问题，无法满足健康消费品快速升级迭代等发展需求。自建厂房有助于构 建东阿阿胶健康消费品领域核心优势。 北京商报讯（记者 丁宁）2月10日晚间，东阿阿胶（000423）发布公告称，公司拟以14.85亿元（其中固 定资产投资14.21亿元，铺底流动资金0.64亿元）的自有资金投资建设健康消费品产业园项目，用于药食 同源食品、保健品、功能性食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商 分拣及药品成品仓储等。 ...

三、定增 1、江淮汽车：公司向姚志超、葛卫东等8名投资者合计发行了7016.84万股股份，发行价格为49.88元/ 股，募集资金总额为约35亿元；其中，私募大佬葛卫东耗资约10亿元认购了2004.81万股。 2、新瀚新材：拟定增募资不超10亿元用于高性能树脂等建设项目。 3、楚天龙：拟定增募资不超7.6亿元用于创新应用安全产品研发及产业化等项目。 四、对外投资、日常经营 1、东阿阿胶：拟以14.85亿元投资建设健康消费品产业园项目。 一、复牌 *ST立方：股价波动核查工作已完成，明起复牌。 二、并购 太阳能：全资子公司收购金华风凌新能源开发100%股权，交易金额为5.27亿元。 4、运机集团：全资子公司签署13.31亿元EPC总承包合同 约占公司2024年度经审计营业收入的86.66%。 8、康达新材：全资子公司拟6.46亿投资建设年产3万吨聚亚芳基醚（PAE）项目。 五、业绩变动 中芯国际：第四季度净利润12.23亿元，同比增长23.2%，主要是由于本季度晶圆销售量增加、产能利用 率上升及产品组合变动所致。 晚间公告 *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 5、中钨 ...

北京商报讯（记者 王寅浩 宋雨盈）2月10日，东阿阿胶发布公告称，公司拟以14.85亿元（其中固定资 产投资14.21亿元，铺底流动资金0.64亿元）的自有资金投资建设健康消费品产业园项目，用于药食同源 食品、保健品、功能性食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣 及药品成品仓储等。 ...

业绩方面，2024年以来，华润医药归母净利润持续下滑。2024年，华润医药实现营收约2577亿元，同比 增长5.3%；归母净利润约33.51亿元，同比下滑13.06%。2025年上半年，实现营收约1319亿元，同比增 长2.54%；同期归母净利润约20.77亿元，同比下滑20.30%。 据企查查，截至2026年2月10日，华润医药及其子公司华润医药投资共持有天麦生物科技23.75%股权。 其中，华润医药投资直接持股20%，系天麦生物科技的第一大股东。 此次华润医药出售其持有的天麦生物科技大部分股份，业内认为，一方面，是华润系聚焦主业剥离非核 心资产之举，另一方面，天麦生物科技重点布局的口服胰岛素上市失败也是影响因素之一。 2025年12月29日，国家药监局网站显示，天麦生物科技参股公司合肥天汇生物科技有限公司申请的重组 人胰岛素肠溶胶囊（ORMD-0801）收到药品通知件，即未能获批上市。ORMD-0801是重组人胰岛素肠 溶胶囊，口服给药，用于需要用胰岛素的糖尿病患者的治疗。该品种最初由Oramed Pharmaceutical Inc. 研发，从2015年底开始，天麦生物与Oramed Pharmaceu ...

Core Viewpoint - China Resources Pharmaceutical (华润医药) announced that its non-wholly owned subsidiary, Dong'e Ejiao (东阿阿胶), has decided to invest in and construct a health consumer goods industrial park, which will enhance its production capabilities and support the growth of its health consumer goods business [1][2]. Group 1: Investment and Construction Details - The health consumer goods industrial park is expected to include manufacturing facilities for health consumer products (such as pharmaceuticals, health foods, and functional foods), along with supporting warehousing, logistics facilities, quality inspection centers, new product incubation centers, and e-commerce sorting and finished product warehouses [1]. - The total area of the health consumer goods industrial park is approximately 406,800 square meters, with a proposed construction area of 151,100 square meters, which will include production facilities for Ejiao cakes, Ejiao dates, and Ejiao powder, as well as comprehensive warehouses and other storage facilities [1]. - The total investment for the project is estimated to be around RMB 1.485 billion, with fixed asset investment amounting to approximately RMB 1.421 billion and working capital of about RMB 64 million [1]. Group 2: Strategic Importance - The investment and construction of the health consumer goods industrial park is a necessary requirement for Dong'e Ejiao to implement its "1238" strategy, aiming to create a model for high-quality development in traditional Chinese medicine [2]. - The project is designed to establish a dual-driven business growth model combining pharmaceuticals and health consumer goods, fostering a second growth curve while addressing the urgent needs for the development of health consumer goods [2]. - The existing industrial park faces limitations in expansion and capacity bottlenecks, which hinder the ability to meet the rapid upgrades and iterations in health consumer goods, making the new construction essential for maintaining competitive advantages [2].

Group 1 - The company Huaren Pharmaceutical (03320) announced that its non-wholly owned subsidiary Dong'e Ejiao (000423.SZ) has decided to invest in and construct a health consumer goods industrial park [1] - The health consumer goods industrial park is expected to include manufacturing facilities for health consumer products (such as pharmaceuticals, health foods, and functional foods), along with supporting warehousing and logistics facilities, quality inspection centers, new product incubation centers, and e-commerce sorting and finished product warehouses [1] - The total area of the health consumer goods industrial park is approximately 406,800 square meters, with a proposed construction area of 151,100 square meters, including production facilities for Ejiao cakes, Ejiao dates, and Ejiao powder, as well as comprehensive warehouses and other storage facilities [1] Group 2 - The investment and construction of the health consumer goods industrial park is a necessary requirement for Dong'e Ejiao to implement its "1238" strategy, aiming to create a model for high-quality development in traditional Chinese medicine and establish a dual-driven business growth model of pharmaceuticals and health consumer goods [2] - The existing industrial park of Dong'e Ejiao faces limitations in expansion area and capacity bottlenecks in major production lines, which cannot meet the rapid upgrading and iteration needs of health consumer products [2] - Building the new facilities will help Dong'e Ejiao establish a core advantage in the health consumer goods sector, with a focus on Ejiao series products, enhancing brand regional recognition, and strengthening core competitiveness [2]

格隆汇2月10日丨东阿阿胶(000423.SZ)公布，公司拟以14.85亿元（其中固定资产投资14.21亿元，铺底 流动资金0.64亿元）的自有资金投资建设健康消费品产业园项目，用于药食同源食品、保健品、功能性 食品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣及药品成品仓储等。 ...

Core Viewpoint - China Resources Pharmaceutical (03320.HK) announced that its non-wholly owned subsidiary, Dong'e Ejiao Co., Ltd. (listed on Shenzhen Stock Exchange, stock code: 000423), has decided to invest in and construct a health consumer products industrial park [1] Group 1 - The proposed health consumer products industrial park is expected to include manufacturing facilities for health consumer products such as pharmaceuticals, traditional food, health supplements, and functional foods [1] - The industrial park will also feature supporting warehousing and logistics facilities, a quality inspection center, a new product incubation center, e-commerce sorting, and finished product warehouses [1]